United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Anthem Biosciences (NSE: ANTHEM) Q2 FY26 results: Can strong CRDMO tailwinds keep driving profitability? Anthem Biosciences Q2 FY26 results reveal strong CRDMO-led growth and 44.5% EBITDA margins. Find out what’s driving investor sentiment and what’s next. byVenkateshNovember 9, 2025